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ABSTRACT
Omi/HtrA2 is a mitochondrial serine protease that is known to translocate to the cytoplasm upon
induction of apoptosis and to activate caspase-dependent and caspase-independent cell death.
The molecular mechanism of Omi/HtrA2’s function is not clear but involves degradation of
specific substrates. These substrates include cytoplasmic, mitochondrial, as well as nuclear
proteins. We have isolated a new Omi/HtrA2 interactor, the THAP5 protein. THAP5 is a fifth
member of a large family of transcription factors that are involved in cell proliferation, apoptosis,
cell cycle control, chromosome segregation, chromatin modification and transcriptional
regulation. THAP5 is an approximately 50kDa nuclear protein, with a restricted pattern of
expression. Furthermore, there is no mouse or rat homolog for this protein. THAP5 mRNA is
highly expressed in the human heart but some expression is also seen in the brain and skeletal
muscle. The normal function of THAP5 in the heart or heart disease is unknown. THAP5
protein level is significantly reduced in the myocardial infarction (MI) area in the heart of
patients with coronary artery disease (CAD). This part of the heart sustains most of the cellular
damage and apoptosis.

Our data clearly show that THAP5 is a specific substrate of the

proapoptotic Omi/HtrA2 protease and is cleaved and removed during cell death. The molecular
mechanism of THAP5’s function is unclear. THAP5 can bind to a specific DNA sequence and
repress transcription of a reporter gene. Our work suggests that THAP5 is a tissue specific
transcriptional repressor that plays an important role in the normal function of the human heart as
well as in the development of heart disease.
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CHAPTER 1: GENERAL INTRODUCTION
Omi/HtrA2 is a serine protease and a homolog of the bacterial high temperature requirement A
(HtrA/DegP) protein [1]. It was originally identified as an interactor of Mxi2, an alternatively
spliced form of p38 stress activated kinase, using the yeast two-hybrid system [1]. It was also
isolated independently as an interactor of Presenilin-1 (PS-1) by another group [2]. Full-length
Omi is a nuclear encoded 458 amino acid protein, which is designated into the following
domains; mitochondrial targeting sequence (MTS) at its amino terminus, a transmembrane
segment (TM), inhibitor of apoptosis protein (IAP) binding motif (IBM), serine protease domain
and a PDZ domain at the carboxyl terminus [1-4]. Omi undergoes autocatalysis at Ala133
thereby removing the amino terminal region including the MTS and TM domains and exposing
the IBM (AVPS) motif. The IBM motif is very similar to Drosophila IAP inhibitor proteins
Reaper, Hid and Grim and their mammalian counterpart Smac/DIABLO [4-8]. The figure below
sows full length Omi/HtrA2 and its autocatalytic processing.
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Figure 1: Schematic Diagram of Omi/HtrA2 and its N-terminal processing
Upon induction of apoptosis, Omi/HtrA2 gets released into the cytoplasm where it binds to IAPs
and proteolytically degrades them, thereby activating the caspase cascade and apoptosis [4, 5].
In addition, it can also activate caspase independent apoptosis that involves its proteolytic
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activity [8]. Homotrimerization of Omi/HtrA2 has been shown to be essential for the protease
activity in addition to the presence of the PDZ domain that plays a regulatory role in proteinprotein interactions [3].

Omi/HtrA2 is predominantly present in the mitochondrial

intermembrane space (IMS), but it has also been found in the endoplasmic reticulum (ER) and
nucleus [1, 2, 9, 10]. The mechanism of its pro-apoptotic activity involves interaction and
degradation of specific substrates that includes mitochondrial, cytoplasmic and nuclear proteins.
The cytoplasmic interacting proteins of Omi/HtrA2 include Inhibitor of Apoptosis proteins
(IAPs) such as XIAP, cIAP1, cIAP2, Apollon/Bruce, PED/PEA15, and receptor-interacting
protein RIP1 [11-14]. The nuclear interactors include Grim-19, WARTS, p73, and Wilms’
Tumor Suppressor protein (WT1) [9, 15-17]. Several of these interactions are mediated via the
PDZ domain and the protease activity of Omi/HtrA2 is always necessary and required for its proapoptotic function. The table below summarizes some of the known substrates and interactors of
Omi reported so far.
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Table 1: List of known interactors of Omi/HtrA2
Protein

Localization

Function

References
[11, 13, 14]

cIAP1, cIAP2,
XIAP,
Apollon/Bruce

Cytosol

Inhibitor of apoptotic proteins

Ped/Pea15

Cytosol

Antiapoptotic protein

[12]

Rip1

Cytosol

Apoptosis, TNF-a signaling

[13]

EndoG

[18]

Presenilin-1,APP,
-secretase

Mitochondria Endonuclease proapoptotic
protein
Mitochondria Precursors of b amyloid
senile plaques

Hax-1

Mitochondria Antiapoptotic protein

[36]

P73

Nucleus

[17]

WARTS

Nucleus

Grim-19
WT1

Nucleus/
Cytoplasm
Nucleus

Tumor Suppressor, p53
family of proteins
Tumor Suppressor, G1/S cell
cycle block
Apoptotic protein

[15]

THAP5

Nucleus

Transcription factor/tumor
suppressor
Transcription factor/ Cell
Cycle (G2/M block)

[21, 22, 23]

[9]
[16]

[71]

Function of Omi/HtrA2 in the mitochondria
It is to be noted that the pro-apoptotic function of Omi/HtrA2 comes to play when it is released
into the cytoplasm from the mitochondria.

However, while confined in the mitochondria

Omi/HtrA2 seems to have yet another function distinct from its pro-apoptotic activity. The other
function of Omi/HtrA2 in mitochondria is not yet known, but it is speculated to play a role in cell
survival thereby contributing to maintenance of mitochondrial homeostasis [19]. Disturbance of
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this function is linked to the development of several disorders including neurodegeneration and
tumors.
A single missense mutation Ser276Cys in the protease domain of Omi/HtrA2 results in Motor
Neuron Degeneration2 (Mnd2) disease in mice [19, 20]. Mnd2 homozygous mice display
striking similarities with Parkinson’s disease (PD) phenotype such as lack of bodily
coordination, reduced motility and tremor.

They also suffer from muscle wasting,

neurodegeneration, significant reduction in the size of organs such as heart, kidneys, spleen and
thymus and death within 40 days of birth [20]. A similar phenotype results in Omi/HtrA2
knockout mice as well [19]. The loss of Omi/HtrA2 has been shown to result in the selective loss
of striatal neurons, accumulation of unfolded proteins in mitochondria, disruption of
mitochondrial respiration and also increased susceptibility to apoptotic stimuli [19].
Omi/HtrA2 and neurodegeneration
Recently, two single nucleotide polymorphisms in the Omi/HtrA2 gene that cause missense
mutations (A141S and G399S) have been identified in relation to Parkinson’s disease [21]. In all
cases, these mutations destroy/ severely impair the proteolytic activity of the enzyme. Some
studies have also implicated Omi/HtrA2 in the development of Alzheimer’s disease. Originally,
Omi/HtrA2 was identified as an interactor of Presenilin-1 in yeast two-hybrid screening [2].
This was followed by another study which showed that the C-terminal portion of Presenilin-1
can interact and enhance the proteolytic activity of Omi/HtrA2 [22]. More recent work has
shown that Omi/HtrA2 is involved in the processing of APP [23] and can also interact with
gamma-secretase [24], suggesting an important role in Alzheimer’s disease as well and possibly
some other neurodegenerative disorders such as Huntington’s disease [25].
4

Omi/HtrA2 in ischemia/reperfusion (I/R) injury
Omi/HtrA2 shows ubiquitous expression in human tissues, and the proteolytic activity of the
protein is significantly upregulated upon ischemia/reperfusion (I/R) injury. Not so long ago, a
specific inhibitor of Omi/HtrA2 namely ucf-101(5-[5-(2-nitrophenyl)furfuryl iodine]1,3diphenyl-2-thiobarbituric acid was characterized [26]. This inhibitor has been used successfully
in I/R studies in different organs. Using a mouse model of kidney I/R injury, it has been shown
that inhibiting Omi/HtrA2 by use of ucf-101 or downregulating the protein by siRNA
interference can confer significant protection to kidney cells from cisplatin or I/R mediated
apoptosis [26-28]. Recent work has shown that HtrA2 gets translocated to the cytosol from the
mitochondria where it promotes death of cardiomyocytes. Use of ucf-101 results in decrease in
myocardial apoptosis along with reduction in infarct size, recovery of mean arterial blood
pressure and improvement in contractile dysfunction ([29-31]. Not only that, work by Althaus et
al also has shown that inhibiting Omi/HtrA2 prior to brain ischemia in rats significantly reduced
cellular damage and conferred neuroprotection [32].
Omi/HtrA2 in cancer
Besides Omi/HtrA2’s role in neurological disorders, a lot of recent work has identified potential
involvement of the protein in tumor development as well. Omi/HtrA2 has a cell-type specific
varied expression levels in several tumors at different stages in comparison to normal tissues
[33]. Omi/HtrA2 has been shown to be expressed in lower levels in endometrial and ovarian
cancers [34], whereas shows higher expression in prostate cancer and many advanced gastric
adenocarcinomas [34, 35]. Interestingly Omi/HtrA2 has also been shown to be involved in
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anoikis; a form of apoptosis caused by the disruption of cell attachment and may be possibly
helping in removing cancer cells [36].
All these studies put together, seem to point to the fact that Omi/HtrA2 might have an important
cell survival function depending on the subcellular localization. One of the approaches used in
the Zervos’ laboratory to study Omi/HtrA2 function is employing the Yeast Two-hybrid System
to identify interacting partner proteins. These interacting proteins could be new substrates of
Omi/HtrA2 or modulators of its proteolytic activity. In one such screen two new Omi/HtrA2
interactors were isolated. One of them is Hax-1 (HS-1 associated protein X-1), a mitochondrial
anti-apoptotic protein that serves as a substrate for Omi/HtrA2 [37]. Hax-1 gets cleaved in the
mitochondria before Omi/HtrA2 translocates to the cytoplasm suggesting that it precedes the
cleavage of IAPs that takes place in the cytoplasm [37]. Our work identified a central role for
Hax-1 and Omi/HtrA2 in regulation of apoptosis in mammalian cells [37].
The other interactor we isolated is called THAP5, whose function is yet to be characterized and
which constitutes the topic of interest of my dissertation. THAP5 belongs to the family of THAP
proteins, which are a recently described evolutionarily conserved family of cellular factors [38].
The following chapters of the dissertation will give a detailed characterization of this novel
transcription factor which is believed to be important in various activities such as transcription
repression, cell cycle arrest, and DNA damage response and also implicated in Coronary Artery
Disease (CAD) and several tumors including melanoma.
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CHAPTER 2: THAP5 IS A HUMAN CARDIAC SPECIFIC INHIBITOR OF
CELL CYCLE THAT IS CLEAVED BY THE PRO-APOPTOTIC
OMI/HTRA2 PROTEASE DURING CELL DEATH
Introduction
Omi/HtrA2 is a mitochondrial serine protease that has an essential role in both mitochondrial
homeostasis as well as cell death [13]. Most of the studies on Omi/HtrA2 have substantially
contributed to our understanding of the mechanism of its pro-apoptotic function. On the contrary
very little is known about its normal function within the mitochondria. Upon induction of
apoptosis, Omi/HtrA2 is released to the cytoplasm where it participates in caspase-dependent
and caspase-independent cell death [4-8]. The mechanism of its pro-apoptotic activity involves
degradation of specific substrates that includes mitochondrial protein HAX-1, cytoplasmic
proteins XIAP, PEA/PED, and Apollon/Bruce [11, 12, 14, 37, 39] as well as, nuclear factors
Grim-19, WARTS, and p73 [9, 16, 17, 40].
The protease activity of Omi/HtrA2 is always necessary and essential for its pro-apoptotic
function. We have used the yeast two-hybrid system to isolate and characterize new Omi/HtrA2
interacting proteins [26]. These interacting proteins could be new substrates of Omi/HtrA2 or
modulators of its proteolytic activity. Previous studies have shown that the proteolytic activity
of Omi/HtrA2 can be regulated through specific protein-protein interactions mediated via its
PDZ-domain [41]. In this report, we describe one such new Omi/HtrA2 interactor, the THAP5
protein. The THAP (Thanatos-Associated Protein) family of proteins comprises a group of
nuclear factors defined by the presence of an approximately 90-residue protein motif (the THAP
domain) [38]. THAP domains are atypical zinc fingers with specific zinc-dependent DNA
binding activity and show similarity to the site-specific DNA-binding domain of the P element
7

transposase from Drosophila [38, 42]. THAP proteins are transcription factors and the limited
information that exists on their function suggests that, they might be involved in gene regulation,
cell cycle control, and/or apoptosis [43-45]. The figure below shows a schematic diagram of the
human and drosophila THAP proteins.

Figure 2: Schematic Diagram of Human and Drosophila THAP proteins
THAP5 is the fifth member in the twelve-member family of human THAP proteins and is unique
since outside its THAP domain, it shares no sequence homology to any other reported protein.
THAP5 interacted with Omi/HtrA2 both in yeast and mammalian cells under pro-apoptotic
conditions where Omi/HtrA2 is known to be released from mitochondria to the cytoplasm.
Furthermore, THAP5 could be cleaved very efficiently in vitro by Omi/HtrA2 protease. Since
very little is known about the function of THAP5 we performed a detailed study to characterize
8

its normal function and the significance of its interaction and degradation by Omi/HtrA2. We
found THAP5 to be a tissue specific nuclear factor that is predominantly expressed in the human
heart. Interestingly, there is no mouse or rat orthologue of THAP5; this is a characteristic of
some THAP-family members since it has also been reported for four other proteins, namely
THAP6, THAP8, THAP9, and THAP10 [44, 46].

The figure below shows a diagram

representing the THAP proteins including the human and Drosophila THAP proteins.
The normal function of THAP5 is the regulation of cell cycle and ectopic expression of the
protein caused cell cycle arrest.

During cell death, THAP5 was cleaved and removed by

Omi/HtrA2 in cells treated with cisplatin and H2O2, but it was not affected in cells treated with
etoposide and camptothecin.

Using the ucf-101 inhibitor of Omi/HtrA2, we could very

effectively block THAP5 degradation and protect cells from undergoing apoptosis.

The

degradation of THAP5 seen during experimentally induced cell death or cell injury is a
physiological event that follows cellular damage and was observed in the myocardial infarction
area (MI) of the heart tissues from patients with coronary artery disease (CAD).
Materials and Methods
Yeast Two-Hybrid Screen. We used the yeast two-hybrid system to screen a HeLa as well as
a melanocyte cDNA library as previously described [37].

The bait used was the mature,

proteolytically active form of the Omi/HtrA2 protein (aa 134-458) cloned in the pGilda
(Clontech) bait vector. Several interacting proteins were identified in this screen. One of these
Omi/HtrA2 interactors isolated from the melanocyte cDNA library was a partial clone of a
previously uncharacterized protein called THAP5. The full-length cDNA for THAP5 encodes
395 amino acids and was isolated from a Marathon Ready human heart cDNA library
9

(Clontech). The specificity of THAP5 interaction with Omi/HtrA2 in yeast was tested using
HtrA1, a mammalian homolog of Omi/HtrA2 that has 68% amino acid sequence similarity. The
presence and stability of the recombinant proteins in yeast cells was monitored by Western blot
analysis using LexA-antibodies (for baits) or HA-antibodies (for preys).
Interaction between Omi/HtrA2 and THAP5 in mammalian cells . HEK293 cells were
transfected in duplicates with either pEGFP-C1 empty vector (Clontech) or EGFP-THAP5
plasmid using Lipofectamine 2000 reagent (Invitrogen). EGFP-THAP5 encodes the full-length
THAP5 protein fused in frame to EGFP-C1 vector. Fourteen hours later, half of the cells were
treated with cisplatin (50M) for 10 hours. Cell lysates were prepared using RIPA buffer
(150mM NaCl, 50mM Tris-HCl pH 7.5, 1% NP-40, 0.25% Na-DOC) containing the proteaseinhibitor cocktail (Roche). Approximately 200g of total protein cell lysates were pre-cleared
by mixing with protein G-Agarose beads (Roche) for 1 hour followed by incubation with the
Omi/HtrA2 polyclonal antibody [37] for 2 hours at 4C. Protein G-Agarose beads were then
added and allowed to bind overnight at 4C.

Immunoprecipitates were collected by brief

centrifugation, washed extensively with RIPA buffer, and resolved by SDS-PAGE. They were
then electro-transferred onto a PVDF membrane and probed with a mouse monoclonal GFP
antibody (Santa Cruz Biotechnology) followed by a secondary goat anti-mouse HRP-conjugated
antibody and the immunocomplex visualized by ECL (Pierce). We also performed the reverse of
this experiment by transfecting HEK293 cells with pEGFP-N1-Omi (1-458). Approximately
200g of total protein cell lysates were pre-cleared by mixing with protein G-Agarose beads
(Roche) for 1 hour and then incubated with THAP5 polyclonal antibody, followed by Western
blot using the GFP antibody as described above.
10

Northern blot analysis of THAP5 mRNA expression in human tissues. A human
mRNA tissue blot (Clontech) representing twelve human tissues was probed with a radiolabeled
DNA probe corresponding to THAP5 protein sequence residues 163-395. This DNA sequence is
unique and has no homology to any other known gene in the GenBank. The blot was hybridized
with the radiolabeled probe at 42C, washed at 65C, and subjected to autoradiography [1]. To
verify that equal amount of mRNA was present on each lane, the blot was stripped and re-probed
for -actin mRNA expression.
Degradation Assay. The ability of His-Omi134-458 to cleave recombinant His-THAP5 protein
in vitro was investigated. The full-length cDNA for the THAP5 protein was cloned in frame in
pET-28 vector (Novagen).

Bacterially expressed recombinant His-THAP5 was purified on

nickel-nitrilotriacetic acid (NTA-agarose) affinity resin as described [37]. The synthesis and
properties of the His-Omi134-458 has been previously reported [37]. His-Omi134-458 was incubated
with His-THAP5 in 15L of reaction volume in assay buffer (20mM Na2HPO4 pH 8, 200mM
NaCl and 5% glycerol). In some of the reactions, the ucf-101 inhibitor was used. After various
incubation times at 37C the reactions were stopped through the addition of SDS-sample buffer.
Reaction products were analyzed by SDS-PAGE followed by Coomassie blue staining.
Cell Culture. HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM),
supplemented with 10% fetal calf serum (Hyclone), 2mM L-glutamine, 1.5g/L sodium
bicarbonate, 1mM sodium pyruvate, 50 units/ml penicillin, 50g/ml streptomycin (Invitrogen).
HeLa cells were grown in DMEM supplemented with 10% fetal calf serum, 2mM L-glutamine,
50units/ml penicillin, 50g/ml streptomycin.
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Sub-cellular localization of the THAP5 protein.

To investigate the sub-cellular

localization of the THAP5 protein, the full-length cDNA (aa 1-395) was cloned in frame into
EGFP-C1 vector (Clontech). Furthermore, DNA sequence corresponding to amino acids 1-162
or 163-395 of THAP5 protein were also amplified by PCR and cloned into EGFP-C1 vector.
HeLa cells were grown on glass cover slips in 12-well plates. Approximately 60% confluent
cells were transiently transfected with 1g of the various GFP-constructs using Lipofectamine
2000 Transfection Reagent (Invitrogen).

Twenty-four hours after transfection, cells were

washed and fixed in 4% paraformaldehyde (PFA), permeabilized with 0.2% Triton X-100 and
incubated with Texas red-phalloidin (Molecular Probes) to stain cytoplasm. The cover slips
were then washed and placed on microscope slides using Fluoromount-G as the mounting
solution. Slides were observed using a LSM510 confocal laser-scanning microscope (Zeiss).
The expression and stability of the various GFP-fusion proteins was verified by Western blot
analysis using GFP-specific antibodies (Santa Cruz Biotechnology).
Expression, purification of His-tagged THAP5163-395 protein and antibody
production. PCR was used to amplify DNA sequence corresponding to a partial carboxyl
terminus THAP5 (aa 163-395) polypeptide. The PCR product was cloned in-frame in the
bacterial expression vector pET-28 (Novagen). For protein expression, BL21 (DE3) (Novagen)
bacteria were transformed with pET-THAP5 and single colonies were grown overnight in LB
medium containing Kanamycin. The overnight culture (1ml) was used to inoculate 1L of LB
medium and growth was continued at 37C until the OD600 was approximately 0.8. At this time,
2mM IPTG was added and the culture was placed in a shaking incubator for 4 hours at 25C.
Bacteria were harvested by centrifugation and lysed in a buffer containing 6M Urea, 0.1M
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NaH2PO4, 20mM Tris-HCl pH 8, and a protease inhibitor cocktail (Sigma). The bacterial
suspension was then sonicated and recombinant His-THAP5163-395 protein purified using Ni-NTA
His-Bind Resin (Novagen). The quality of the His-THAP5163-395 protein was monitored by SDSPAGE followed by Coomassie blue staining. To make the polyclonal antibody, 15mg of purified
human His-THAP5163-395 was used to immunize two rabbits. Immunization, production, and
purification of the polyclonal THAP5 antibody were performed by New England Peptide Inc.
Western blot analysis of THAP5 protein expression in var ious human tissues.
Since THAP5 is expressed only in human cells we used a commercially available Western blot
that represents five human tissues (Calbiochem). Each lane of the blot contains 10g of crude
protein extract from the corresponding tissue. We used our THAP5 polyclonal antibody at a
1:5000 dilution. The method and conditions for the Western blot analysis have been previously
described [27, 37].
Cell Cycle Analysis. Human embryonic kidney cells (HEK293) were seeded onto six-well
plates, synchronized with serum starvation [47, 48], and then transiently transfected with EGFPC1 empty vector (Clontech) or EGFP-THAP5 using Lipofectamine 2000 Transfection Reagent
(Invitrogen).

Forty or fifty hours after transfection, cells were washed and fixed in 4%

paraformaldehyde (PFA). The cells were then washed, permeabilized with 0.1% Saponin and
stained with 7-amino-actinomycin D (7-AAD) (5L per 100L of PBS) and incubated for 30
minutes at 37C. GFP positive cells in the transfected population were measured using a
FACSCalibur Flow Cytometer (BD Biosciences) [49] and analyzed using ModFitLT software.
Cell Death Assays.

HeLa cells were treated for 12 hours with different chemicals:

camptothecin (100M), cisplatin (5M), etoposide (20M), H2O2 (0.2mM) and Staurosporine
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(100M). HeLa cells were grown in six-well plates in the appropriate medium until they
reached 70-80% confluency; they were then treated with ucf-101 (20 or 30M) for 20 minutes
followed by cisplatin (5M) or H2O2 (0.2mM) treatment for 12 hours. Cells were detached with
1X Trypsin-EDTA (Gibco), washed twice with ice-cold PBS, half of them were used for
Western Blot analysis and the rest for apoptotic assay. Western Blot analysis was performed as
described [27, 37]. The apoptotic assay was performed according to BD Biosciences protocol.
Briefly, cells were suspended in 1X binding buffer and stained with Annexin V (apoptotic cell)
and 7-AAD (necrotic cells) [50-52]. Samples were analyzed on a FACSCalibur Flow Cytometer
(BD Biosciences).
Expression of THAP5 in the heart of patients with coronary artery disease (CAD).
Human cardiac tissues were prepared as described [53]. Briefly, human cardiac tissue samples
were taken from the left ventricles of failing human hearts that were explanted in the course of
heart transplantation. The study's protocol was approved by the local ethics committee, and
written informed consent given by patients, according to the National Disease Research
Interchange (NDRI). Hearts from patients with end-stage heart failure who were undergoing
cardiac transplantation because of either DCM (Dilated Cardiomyopathy) or CAD (Coronary
Artery Disease) were investigated. Furthermore, healthy donor (HD) hearts that were ultimately
rejected for transplantation because of technical reasons were also included in this study as
healthy tissue control. For Western blot analysis, 100 mg of tissue was ground in liquid nitrogen
and homogenized with an Ultra-Turrax T8 (IKA-werke) in ice-cold lysis buffer containing
150mM NaCl, 20mM Tris-HCl pH 7.6, 1mM CaCl2, 1mM MgCl2, 10% Glycerol, 1% NP40 and
protease and phosphatase inhibitors cocktail (Roche).
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Homogenate was cleared by

centrifugation for 10 min at 14,000 g. Protein concentrations were determined using the Bio-Rad
protein assay (Bio-Rad). Approximately 20g of whole cell extract was resuspended in SDSsample buffer and boiled for 3 minutes. Samples were resolved by SDS-PAGE and electrotransferred onto PVDF membranes (Pall Life Sciences) using a Semi-Dry cell Transfer Blot
(Bio-Rad). 4% nonfat dry milk in TBST buffer was used to block any non-specific binding. The
membrane was incubated with our THAP5 polyclonal antibody (1:5000) followed by a
secondary HRP-conjugated goat anti-rabbit (Jackson ImmunoResearch) (1:15000) and
visualization by ECL (Pierce).
Statistical analysis. All quantitative data are expressed as mean ±SD. Differences among
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s Post-hoc
test. A value of P<0.05 was considered significant.
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Results
Isolation of THAP5 as an Omi/HtrA2 interactor.

We used the yeast two-hybrid

system to isolate Omi/HtrA2 interactors. We screened two different cDNA libraries derived
from HeLa cells and primary human melanocytes. We used two different cDNA libraries in
order to screen as many diverse proteins as possible, including any potential tissue specific
interactors of Omi/HtrA2. Furthermore, one of the cDNA libraries was prepared from primary
cells to avoid a potential problem often seen in cDNA libraries prepared from transformed cell
lines. Cells lines such as HeLa used here often have deregulated expression of genes involved in
cell growth as well as under-representation of pro-apoptotic cDNAs. The bait in this screen was
the LexA-Omi134-458 that represents the mature active form of the Omi/HtrA2 enzyme [37]. The
screen was performed as described and several novel Omi/HtrA2 interacting proteins were
identified [37]. One of the specific interactors from the human melanocyte cDNA library was a
partial polypeptide of THAP5. THAP5 is the fifth member of a recently described twelvemember family of proteins characterized by the presence of a THAP (Thanatos-Greek for death)
motif at the amino terminus of the protein [38]. Using specific primers and RACE we were able
to isolate the full-length cDNA, which was then cloned back into the pGJ4-5 vector and its
interaction with Omi/HtrA2 monitored. Figure 3A shows that full-length THAP5 interacts
strongly with the Omi/HtrA2. Furthermore, the specificity of the interaction was tested using
HtrA1, a human homologue of Omi/HtrA2 that has 68% amino acid sequence similarity. No
interaction was observed in this yeast two-hybrid assay between these two proteins (Fig. 3A).
The expression and stability of the different baits and preys was monitored and verified by
Western blot analysis (results not shown).
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Interaction of Omi/HtrA2 with THAP5 in mammalian cells during apoptosis. To
investigate whether Omi/HtrA2 can interact with THAP5 in vivo, HEK293 cells were transfected
with a construct encoding GFP-THAP5. Cells were treated with cisplatin for 12 hours to induce
apoptosis.

After this time, Omi/HtrA2 antibodies were used to precipitate endogenous

Omi/HtrA2 protein and the presence of any GFP-THAP5 protein in the complex was monitored
by Western blot analysis using a GFP-specific monoclonal antibody (Santa Cruz Biotechnology).
Figure 3B shows that endogenous Omi/HtrA2 interacts with GFP-THAP5 in HEK293 only in
cells treated with cisplatin and undergoing apoptosis. No interaction between Omi/HtrA2 and
GFP-THAP5 was observed under normal non-apoptotic conditions. We also performed the
reverse experiment by transfecting HEK293 cells with GFP-Omi and using the THAP5 antibody
to precipitate endogenous protein and any GFP-Omi associated with it. This experiment also
clearly shows that THAP5 and GFP-Omi can associate in mammalian cells but only during
apoptotic conditions (Fig. 3C)
THAP5 is cleaved by Omi/HtrA2 protease in vitro. To test the ability of Omi/HtrA2
protease to cleave the THAP5 protein in vitro, bacterially made His-THAP5 was incubated with
His-Omi/HtrA2134-458 protease for different time periods.

Figure 3D shows that His-

Omi/HtrA2134-458 was able to degrade the THAP5 protein in this assay. To verify that cleavage
of THAP5 was due to Omi/HtrA2 activity and not by some other contaminated bacterial protease
we used its specific inhibitor ucf-101 [26]. When used in this assay, ucf-101 was able to prevent
the degradation of THAP5 by Omi/HtrA2 (Fig.3D).
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Expression of THAP5: mRNA and protein. Figure 4A is a schematic diagram of the
THAP5 protein. The nucleotide sequence predicts a protein consisting of 395 amino acids. The
THAP domain is located at its amino terminus and shows high homology to the other eleven
members of the human THAP family of proteins. Outside the THAP domain, THAP5 protein
has no similarity to any other known protein sequence that is uploaded in the GenBank. A
coiled-coil region is also predicted at its carboxyl-terminus. Since there is no mouse or rat
orthologs for THAP5, a human Northern blot representing various tissues was used to investigate
THAP5 mRNA expression. THAP5 expression is represented by a specific mRNA band of
approximately 3.2kb (Fig. 4B). THAP5 mRNA shows very high expression in the human heart
and when the blot is overexposed, some expression is also seen in the human brain and skeletal
muscle (Fig. 4B). No expression of THAP5 is detected in any of the other human tissues
represented on this blot. To verify that there is a bona-fide THAP5 protein present in these
human tissues we raised a polyclonal antibody against a recombinant His-THAP5163-395. This
antibody was used on a Western blot containing extracts from various human tissues
(Calbiochem). Figure 4C shows that a 50kDa polypeptide is readily detectable in human heart,
brain, and skeletal muscle. A higher molecular weight band is also detected in the human brain
that corresponds to a phosphorylated form of the same THAP5 protein (unpublished data). The
relative levels of the THAP5 protein versus mRNA in the three human tissues do not correspond
and this is probably due to the poor quality (protein degradation) of the commercially available
human Western blot.
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Sub-cellular localization of the THAP5 protein. The cDNA sequence corresponding to
the full-length THAP5 protein was cloned into the GFPC1 vector. The GFP-THAP5 vector was
transfected into HeLa cells and 24 hours later the sub-cellular localization of the protein was
observed using a confocal microscope as previously described [27]. Figure 5A shows that, the
full-length GFP-THAP5 protein is localized exclusively in the cell nucleus but is excluded from
the nucleoli. There are two discernible domains in the THAP5 protein: (a) the THAP domain
(90aa) present at the amino terminus that shares homology with the corresponding domain in the
other eleven members of the THAP family of proteins and (b) the rest of the THAP5 protein (91395aa) that shows no homology to any other known protein sequence in the data banks.
Therefore, we cloned DNA sequence corresponding to the amino terminus of the protein
including the THAP domain or the unique carboxyl-terminus of THAP5 into the GFP vector in
order to investigate their potential role targeting the protein to the nucleus. Figure 5B shows that
the THAP5 protein that lacks the amino terminus is now predominantly cytoplasmic, whereas the
THAP domain alone localizes exclusively in the cell nucleus (Fig. 5C). Figure 5D is a Western
blot to verify the expression and stability of the three different GFP fusion proteins used in this
experiment.
THAP5 is a potential regulator of cell cycle. Previous reports suggested that some
members of the THAP-family of proteins could inhibit cell cycle progression [43]. Therefore,
we investigated whether ectopic expression of a GFP-THAP5 protein in human embryonic
kidney (HEK293) will interfere with the cell cycle progression. Cells were synchronized and
transfected with GFP-THAP5 or the empty GFP vector and 40 or 50 hours later the percentage of
transfected cells at various points of the cell cycle were estimated.
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Figure 6 shows an

accumulation of GFP-THAP5 expressing cells at the G2/M phase compared to cells expressing
GFP alone forty hours post transfection. This difference becomes more pronounced after fifty
hours where over 28% of the GFP-THAP5 expressing cells were found in the G2/M phase versus
2% of cells transfected with GFP vector.
THAP5 is degraded in cells treated with cisplatin or H 2 O 2 . In order to investigate
whether THAP5 protein is regulated during apoptosis, HeLa cells were treated with various
chemicals known to induce apoptosis including: camptothecin, cisplatin, etoposide, H2O2 and
staurosporine, subsequently cell death was measured using Annexin V staining and Flow
Cytometry [37]. THAP5 protein level was monitored by Western blot analysis of cell extracts
and it was significantly reduced in cells treated with cisplatin or H2O2 (Fig. 7). These chemicals
also induced the maximum cell death (64% and 58% respectively) in this assay. In cells treated
with cisplatin the phosphorylated form of THAP5 (upper band on the blot) was preferentially
cleaved whereas in cells treated with H2O2 both forms of the protein were equally degraded.
Ucf-101 inhibitor prevents THAP5 degradation.

We investigated whether the

Omi/HtrA2 protease is responsible for the degradation of THAP5 observed in HeLa cells during
apoptosis. For this, HeLa cells were treated with cisplatin and the percentage of cell death
monitored by Annexin V staining and Flow Cytometry and the levels of THAP5 protein
monitored by Western blot analysis. HeLa cells treated with 5M cisplatin for 12 hours resulted
in 42% cell death of the population (Fig. 8). The cell death in these cells coincided with a
dramatic reduction in the level of THAP5 protein. We also performed the same experiment in
the presence of two different concentrations of ucf-101, a specific inhibitor of the proteolytic
activity of Omi/HtrA2 [26]. In this case, the percentage of apoptotic cells in the population was
20

reduced to 21%. The ucf-101 inhibitor was also able to protect the degradation of the THAP5
protein implicating Omi/HtrA2 protease in this process.
Expression of THAP5 protein in heart tissues derived from patients with
coronary artery disease. THAP5 expression is highest in the human heart suggesting a
potential role of this protein in the normal function of the cardiomyocytes. We monitored the
protein level of THAP5 in the heart of patients with various heart diseases including Coronary
Artery Disease (CAD) and Dilated Cardiomyopathy (DCM). Figure 9A shows the expression of
THAP5 protein in the remote zone (CAD-RZ), border zone (CAD-BZ), and myocardial
infarction area (CAD-MI) in hearts of three CAD patients. In two of the patients, there is clear
reduction in the level of THAP5 in the CAD-MI area compared to the CAD-RZ and CAD-BZ.
The myocardial infarction area is the part of the heart that sustains maximum injury in CAD.
Therefore, this area is expected to contain most damaged and apoptotic cells. Figure 9B shows
the expression of THAP5 protein in the heart tissue of three patients with dilated cardiomyopathy
(DCM) and three healthy donors (HD). No significant difference is seen in the level of THAP5
protein in the hearts of DCM patients or healthy donors. The blot was also probed with
GAPDH-specific antibody to verify that equal amount of protein extract was used in each lane.
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Discussion
Omi/HtrA2 is a nuclear encoded mitochondrial protease that has homology to bacterial HtrA
chaperones [1, 54, 55]. Recent evidence suggests that Omi/HtrA2 has two distinct functions
both requiring its protease activity. Omi/HtrA2 can be a pro-apoptotic protein as well as a prosurvival factor depending on its sub-cellular location. The pro-survival function of Omi/HtrA2
was based on studies on motor neuron degeneration 2 (mnd2) mice that carry a single mutation
affecting the proteolytic activity of Omi/HtrA2 [20]. Mnd2 homozygous animals suffer muscle
wasting, neurodegeneration, and die by six weeks of age. Based on these studies, it is assumed
that the primary function (physiological function) of Omi/HtrA2 in mammalian cells is to
somehow maintain mitochondrial homeostasis necessary for cell survival [19, 20]. The other
function of Omi/HtrA2 (pathological function) becomes operational only under conditions
leading to cell death where Omi/HtrA2 is released to the cytoplasm as a pro-apoptotic protein
and participates in caspase-dependent as well as caspase-independent apoptosis [4, 5, 8].
Most of the studies reported so far have provided significant new information on the mechanism
of Omi/HtrA2’s pro-apoptotic function but little if nothing on its pro-survival function is known.
Omi/HtrA2, when released to the cytoplasm, binds and degrades several substrates including
IAPs, PEA/PED, and Apollon/Bruce [11, 12, 14, 39]. Some of these proteins are clearly antiapoptotic factors and their removal by Omi/HtrA2 can undoubtedly accelerate cell death. Others
have a more obscure function and their association and cleavage by Omi/HtrA2, in the context of
inducing cell death, is more difficult to explain.

In the present study, we report the

characterization of THAP5, the fifth member of the THAP family of proteins as a specific
interactor and substrate of Omi/HtrA2 protease. THAP proteins comprise a recently described
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family of cellular factors with unique structural and functional characteristics. They are defined
by the presence of the THAP domain, an atypical zinc-dependent DNA-binding domain of
approximately 90 amino acids.
There are 113 THAP proteins listed in the databases and in humans, there are 12 distinct proteins
(THAP0-THAP11) [38]. All 12 human THAP proteins have a single THAP domain at their
amino terminus. In Drosophila there are seven THAP proteins two of which contain more than
one THAP domain, CG14860 has two THAP domains and the CG10631 is predicted to have as
many as 27 THAP domains [38]. THAP domains are unique as DNA binding motifs due to a
significant similarity with the DNA binding domain of Drosophila P element transposase. This
similarity includes the size of the THAP domain, its location in the protein and the conservation
in the number and residues that define the domain [38]. THAP0, also known as the deathassociated protein DAP4/p52rIPK, was identified as one of the genes induced by IFN--induced
apoptosis and in an independent study as an interactor of PKR protein kinase [56, 57]. THAP1
was originally defined as a pro-apoptotic nuclear factor localized at the promyelocytic leukemia
nuclear bodies (PML NBs) and interacting with prostate-apoptosis-response-4 (Par-4) protein
[45].
Since very little is known about THAP5 we embarked on a detailed study beginning with its
expression. In human tissues THAP5 mRNA is predominantly expressed in the human heart
although low expression is also detected in skeletal muscle and brain. More significantly, we
found no orthologs for THAP5 in mouse (Mus musculus) or rat (Rattus norvegicus). The closest
orthologs were detected in Macaca fascicularis, Bos taurus, and Gallus gallus. The absence of
orthologs in mouse and rat has also been reported for four other members of the THAP family,
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the THAP6, THAP8, THAP9, and THAP10 proteins [46]. It was suggested that some THAP
genes might have originated from a domestication event of a single copy of P element
transposase that took place in the human lineage after it had diverged from the rodent lineage
[42]. Alternatively, THAP gene domestication might have occurred earlier in the evolution but
was later lost in the lineage leading to rodents [42].
To verify that THAP5 is a bona fide human protein, we raised a polyclonal antibody against the
unique part of the protein (aa163-395) that does not include the THAP domain. This polyclonal
antibody clearly recognized a specific band of 50 kDa, corresponding to THAP5 in human heart,
skeletal muscle, and brain. In human brain a 52kDa polypeptide was also detected that could
possibly correspond to a phosphorylated form of the same THAP5 protein.

The THAP5

antibody did not detect any specific protein bands when tested against various mouse or rat tissue
extracts (results not shown).
To investigate the sub-cellular localization of THAP5, we expressed the full-length protein fused
to GFP in HeLa cells. The fusion protein, GFP-THAP5, shows exclusive nuclear localization
but is excluded from the nucleoli. The amino terminus of the protein that includes the THAP5
domain is responsible for its nuclear localization. This is the part of the protein implicated in
DNA binding as well as protein-protein interactions [58]. The interaction with Omi/HtrA2 is
mediated by the carboxyl-terminus of THAP5 that binds the PDZ-domain of Omi/HtrA2. The
carboxyl-terminus of THAP5 has the amino acid sequence EVTMI* that conforms to the
consensus sequence for PDZ (Omi) binding proteins [41, 59].
Previous studies have shown two members of the same family, THAP1 and THAP11 can
regulate cell proliferation [43, 60]. Furthermore, genetic studies using C. elegans support a role
24

of THAP proteins in cell cycle regulation. These studies demonstrated a genetic interaction
between LIN-35/Rb, which is the C. elegans retinoblastoma homologue and four C. elegans
THAP proteins, LIN-36, LIN-15B, LIN-15A, and HIM-17. LIN-36 and LIN-15B are known
inhibitors of G1/S cell cycle transition [44, 61-65]. Also, in zebrafish the ortholog of the cell
cycle transcription factor E2F6 has a THAP domain and functions as a repressor of E2-Fdependent transcription during S phase [66]. Based on these reports we decided to investigate if
THAP5 plays any role in the regulation of cell cycle.
For these studies, we ectopically expressed GFP-THAP5 in a human embryonic kidney
(HEK293). This cell line expresses endogenous THAP5 protein and can be transfected with high
efficiency. The results from these experiments clearly show, GFP-THAP5 had a dramatic effect
blocking the progression of transfected cells through the cell cycle progression and causing high
accumulation of cells at the G2/M phase. The mechanism by which THAP5 inhibits cell cycle is
not known and it most likely will involve the direct regulation of cell cycle genes. THAP5 has
an atypical zinc finger domain at its amino terminus that can bind to specific DNA sequences on
different promoters. A recent study showed that another member of the same family, THAP11,
could inhibit cell cycle by binding to the promoter of c-Myc and down-regulating its expression
[60].
To investigate the role of the THAP5-Omi/HtrA2 interaction during apoptosis, HeLa cells that
normally express THAP5 were treated with various chemicals to induce cell death. Under these
conditions, Omi/HtrA2 is released from mitochondria and becomes a pro-apoptotic protein. In
these experiments, the THAP5 protein was cleaved in cells treated with cisplatin or H2O2 and the
degree of THAP5 degradation increased proportionally with the rate of apoptosis in the cell
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population. No significant cleavage of THAP5 was seen in cells treated with Etoposide and
Camptothecin but these chemicals also caused minimal cell death in this protocol and cell line
used for these experiments. We used a specific inhibitor to show that Omi/HtrA2 is responsible
for THAP5 degradation. This inhibitor, ucf-101, was developed in our laboratory and has been
extensively studied in various systems of cell death [26, 31, 37]. When the ucf-101 inhibitor was
used, it clearly blocked THAP5 cleavage and protected cells from apoptosis.
THAP5 is hyper-expressed in the human heart but there are no rodent orthologs, therefore
limiting the type of studies that can be done to investigate its potential involvement in the
development or progression of heart disease. We obtained small tissue samples from patients
with several human heart diseases including coronary artery disease (CAD) and dilated
cardiomyopathy (DCM). In CAD patients, we were able to detect a decrease in the THAP5
protein level in the myocardial infarction (MI) area when compared to remote zone (RZ) or
border zone (BZ) areas of the same heart. These results, though preliminary, suggest that during
pathological conditions resulting in myocardial cell death, such as MI, the THAP5 protein
decreases significantly in areas of the heart that sustained maximum cell damage. There was no
difference in THAP5 protein levels in DCM patients compared to normal (donor) heart.
Previous studies have shown that Omi/HtrA2 is a key player in myocardial ischemia/reperfusion
injury [29]. Furthermore, inhibition of the proteolytic activity of Omi/HtrA2 using the ucf-101
inhibitor improved post-ischemic myocardial function and reduction of the myocardial infarct
size [29-31].
THAP5 is the first human, heart-specific substrate of Omi/HtrA2 identified thus far. Under
normal, physiological conditions THAP5 functions as an inhibitor of cell cycle. This dual
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function of THAP5 supports previous studies that have shown the existence of a cross talk
between cell cycle control and apoptosis in cardiomyocytes. For example, over-expression of
the cell cycle inhibitor p57kip2 in cardiomyocytes was shown to attenuate ischemia-reperfusion
injury in the mouse heart [67]. In another study, cyclin A/cdk2 activation was involved in
hypoxia-induced apoptosis in cardiomyocytes [68]. The hyper-expression of THAP5 in human
heart and its regulation during cell death by Omi/HtrA2 suggests this pathway plays a significant
in the normal function of the heart. Furthermore, THAP5 might be involved in the development
and progression of heart disease especially in coronary artery disease.
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Figure 3: THAP5 is an interactor and substrate of Omi/HtrA2 protease.
A, Yeast colonies were transformed with plasmids encoding the indicated baits and full length THAP5
cloned into the prey vector. The specificity of THAP5 and Omi/HtrA2 interaction was verified using a
closely related homologue, the HtrA1 protein. Blue color results from a positive protein-protein
interaction. B, HEK293 cells were transfected with EGFP, EGFP-THAP5 or GFP-Omi. Twelve hours
after transfection one plate was treated with Cisplatin to induce apoptosis and one plate was used as
control. A polyclonal Omi/HtrA2 antibody was used for immunoprecipitation. The immunoprecipitated
complex was resolved on SDS-PAGE, transferred and the presence of GFP-THAP5 fusion protein
detected using a specific anti-GFP antibody. Lane 1 shows crude lysates of GFP-THAP5 transfected
cells. Lane 2 shows Co-IP lysates obtained from cells transfected with GFP empty vector. Lane 3 shows
Co-IP lysates obtained from cells transfected with GFP-THAP5 control cells and lane 4 shows Co-IP
lysates obtained from cells transfected GFP-THAP5 and then treated with cisplatin. C, Shows the reverse
experiment described in Fig 1B. HEK293 cells were transfected with GFP-Omi and THAP5 antiserum
was used in the Co-IP and anti-GFP on the Western blot to detect the GFP-Omi. Lane 1 shows total cell
lysates of GFP-Omi transfected cells. Lane 2 shows Co-IP lysates obtained from cells transfected with
GFP empty vector. Lane 3 shows Co-IP lysates obtained from cells transfected with GFP-Omi control
cells and lane 4 shows Co-IP lysates obtained from cells transfected GFP-Omi and then treated with
cisplatin. In both Figures 1B and 1C THAP5 was co-precipitated with Omi/HtrA2 but only in cells where
apoptosis was induced. D, Purified His-THAP5 was incubated with His-Omi134-458 at 37°C for the
indicated time periods. For some assays, Omi/HtrA2 was pre-incubated with ucf-101 inhibitor 10 min
prior to addition of His-THAP5. The reactions were resolved on SDS-PAGE and the gel stained with
Coomassie Blue. Lane 1, His-THAP5 control (400ng); lane 2, His- Omi134-458 control (400ng), lanes 3, 5,
7 and 9, His-Omi+His-THAP5 at different time points; lane 4, 6, 8, and 10, His-Omi + His-THAP5+ ucf101 (50M); lane 11, His-THAP5 + ucf-101 control
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Figure 4. Expression of THAP5: mRNA and protein in human tissues.
A, Schematic representation of the THAP5 protein encoded by 395 amino acids. The light gray box
represents the 90aa THAP domain, which is characteristic of all THAP proteins. B, Northern blot
analysis of THAP5 expression in human tissues. A commercially available Northern blot (Clontech)
containing 2g/lane poly (A) mRNA from various adult human tissues was probed with 32P-THAP5 (5391342) cDNA. A single transcript was detected of about 3.2 kb. The blot clearly shows high expression of
THAP5 in the human heart, some expression was also seen in skeletal muscle and brain. -actin probe
was used to verify that equal amounts of mRNA were present in each lane. C, Western blot analysis of
THAP5 protein in multiple human tissue; A commercial western blot (INSTA-blot Calbiochem)
containing 15g/lane of total protein from adult human tissues was incubated with rabbit-polyclonal antiTHAP5 antibody followed by a secondary antibody, HRP-conjugated goat anti-rabbit and
chemiluminescence detection.
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Figure 5. Sub-cellular localization of the THAP5 protein in mammalian cells.
A, Confocal image of HeLa cells transfected with GFP-THAP51-395 shows exclusive nuclear localization
(green in panel A”). B, HeLa cells transfected with GFP-THAP5163-395 show cytoplasmic localization
(green in panel B”). C, HeLa cells transfected with GFP-THAP51-162 show exclusive nuclear localization
(green in panel C”) of this protein. The cells were also stained with Texas red-phalloidin (Molecular
Probes) that stain actin filaments (red). Nomarski/DIC images of the same cells are shown in panel A’,
B’ and C’ respectively. D, The stability of EGFP-fusion proteins was monitored by Western blot analysis
using an anti-GFP antibody. Equal amounts of whole-cell lysates, obtained 24 hrs post-transfection were
subjected to SDS-PAGE followed by Western blot analysis using anti-GFP monoclonal antibody as
described in Materials and Methods. Lane 1, lane 2 and 3 represent lysates obtained after transfection of
HeLa cells with GFP- THAP51-395, GFP-THAP5163-395, and GFP- THAP51-162 respectively.
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Figure 6. Over-expression of GFP-THAP5 causes accumulation of cells in G2/M phase.
HEK293 cells were transiently transfected with GFP vector alone or GFP-THAP5. 40hrs and 50hrs post
transfection cells were stained with 7-AAD and the DNA content was analyzed using ModFitLT
software. Panel C represents the percentages of GFP positive cells at different phases of cell cycle 40 hrs
after transfection and panel F represents 50hrs. A, Histogram results from representative experiments in
cells transfected with GFP vector at 40 and D, 50 hours. B, Cells transfected with GFP-THAP5 40 and E,
50 hours show significant increase in the percentage of cells in G2/M phase. Data are means SD of four
independent experiments.
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Figure 7. THAP5 protein level is regulated during apoptosis.
Total cell lysates were prepared from HeLa cells after induction of apoptosis using different chemicals
(Camptothecin, Cisplatin, Etoposide, H2O2 and Staurosporine). A, Cell death was monitored in the
treated cell populations by Annexin V and 7-AAD staining and analyzed by Flow cytometry. B, Cells
extract were prepared followed by Western blot analysis of the same samples. Lane 1 shows lysates from
control, untreated cells, lanes 2, 3, 4 show cell extracts from HeLa treated with the chemical indicated
above. actin antibody was used to verify that equal amounts of protein were present in each lane.
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Figure 8. A specific inhibitor of Omi/HtrA2 blocks THAP5 cleavage and protects HeLa
cells from apoptosis.
A, HeLa cells were treated with 20 or 30M of ucf-101 and apoptosis was induced with 5M cisplatin for
12 hours. Apoptosis was monitored using Annexin V and 7-AAD staining and analyzed by Flow
cytometry. B, Extracts were prepared from the same cell population and analyzed by SDS-PAGE and
Western blot analysis using THAP5 antibody. Cisplatin treatment caused a dramatic reduction in THAP5
protein level (lane 2). This corresponds with increased apoptosis in the cell population. When HeLa cells
were treated with ucf-101 followed by cisplatin, the inhibitor substantially protected THAP5 proteins and
the percentage of apoptotic cells was significantly reduced (lanes 3 and 4). actin antibody was used to
verify that equal amounts of protein were present in each lane.
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Figure 9. THAP5 protein levels in heart tissues from patients with coronary artery disease
(CAD).
A, Heart tissue extracts from three patients with coronary artery disease (CAD) were used in a Western
blot to monitor the expression of THAP5 protein. Extracts were prepared from three areas on each heart
corresponding to the remote zone (CAD-RZ), border zone (CAD-BZ), and the infarction (CAD-MI) area.
B, Human heart tissue lysates from three healthy donors (HD 1 to 3) and three DCM patients (DCM 1 to
3) were probed for THAP5 expression.
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CHAPTER 3: THAP5 IS A DNA BINDING PROTEIN AND A
TRANSCRIPTIONAL REPRESSOR WITH A ROLE IN MELANOMA
CELL DEATH
Introduction
THAP proteins are zinc dependent DNA binding proteins involved in several functions such as
cell proliferation, apoptosis, cell cycle, chromosome segregation, chromatin modification and
transcriptional regulation [38]. THAP stands for Thanatos Associated Protein (derived from
Thanatos which means death in Greek) [38]. These proteins are defined by the presence of an
approximately 90 amino acid THAP domain at their amino terminus. THAP domains are
evolutionarily conserved motifs with specific amino acid residues that are necessary for the DNA
binding activity of the THAP proteins [38, 42, 44]. Twelve human THAP proteins (THAP0-11)
have been identified but most of the studies have been focused on THAP0 (DAP4), THAP1,
THAP7 and THAP11 [43, 44, 56-58, 60]. Very little, if anything, is known about the function of
the other members of the THAP family proteins.
The first THAP protein to be studied was THAP0/ DAP4 (death associated protein-4) [56, 57].
THAP0 has been shown to enhance apoptosis caused by the overexpression of MST-1 protein
[69]. THAP1 has been shown to be a nuclear protein associated with promyelocytic leukemia
nuclear bodies and TNF- induced apoptosis [45]. It can also act as a regulator of cell cycle
(G1/S phase) by regulating the expression of the RRM11 gene, a pRb/E2F target protein [43].
THAP7 is a chromatin associated transcriptional repressor protein that recruits histone
deacetylase 3 (HDAC3) and nuclear hormone receptor corepressors (NCoR) [58, 70]. THAP11
has been shown to suppress cell growth by transcriptional downregulation of c-Myc [60]. The
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mouse homolog of THAP11, called Ronin, was identified as an essential factor for
embryogenesis and embryonic stem (ES) cell pluripotency [71].

In our previous work, we identified the THAP5 protein as an interactor and substrate of the
mitochondrial serine protease Omi/HtrA2 [72] (The Am Physiol Soc, used with permission).
THAP5 is a nuclear protein with a restricted pattern of expression and is present predominantly
in the human heart. Furthermore, there is no mouse or rat homolog for THAP5. The closest
orthologs have been detected in monkey, cow and chicken. The absence of mouse/rat homolog
has also been noted in some other THAP proteins, namely THAP6, THAP8, THAP9 and
THAP10 [46]. Our studies showed that THAP5 is an inhibitor of cell cycle and is cleaved by the
pro-apoptotic protease Omi/HtrA2 during cell death [72]. The levels of THAP5 protein are
significantly reduced in the myocardial infarction area of human heart tissues obtained from
patients suffering from coronary artery disease (CAD) suggesting a potential role of this protein
in the development and/or progression of human heart disease [72].

In this work, we extend our studies on the mechanism of the normal function of THAP5 and its
potential role in cell death.

For this, we used human melanoma cells since THAP5 was

originally isolated from a human melanocyte cDNA library [72]. In addition, although THAP5
is mostly expressed in human heart, human heart tissues are hard to obtain and there is no human
heart cell line. Nothing is known about the biological role of THAP5 in melanocytes and
melanoma cells. We found, upon UV or cisplatin treatment of melanoma cells, THAP5 protein
is induced considerably. The induction of THAP5 mirrors the degree of apoptotic cell death in
the melanoma population. Overexpression of THAP5 sensitizes melanoma cells to UV-induced
apoptosis. To further investigate the mechanism of THAP5 function we used an in vitro binding
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selection and identified an 11-nucleotide consensus DNA-binding sequence specifically
recognized by THAP5 protein. In addition to its DNA binding ability, THAP5 was able to
repress the transcription of a reporter gene in a heterologous system. In summary, our work
defines THAP5 as a DNA binding protein that can potentially repress the transcription of target
genes involved in UV or cisplatin-induced damage and cell death of melanoma cells.
Materials and methods
Cell culture.

Melanoma (MEL-2, MEL-18, MMG1, SMYM, 397mel, 624mel, 888mel,

928mel, SKmel23, RPM-ML, PM-WK, and MM-LH), stomach cancer (MNK7 and MNK28),
lung cancer (A549), Ovarian Cancer (ES2), normal monkey kidney (cos7) cell lines were grown
in Life Technologies RPMI 1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10%
heat-inactivated fetal bovine serum (FBS). All cell lines were cultured at 37 ˚C in a humidified
atmosphere containing 5% CO2, as previously described [73]. HEK-293 cells were grown in
Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal calf serum
(Hyclone), 2 mM L-glutamine, 1.5 g/l sodium bicarbonate, 1 mM sodium pyruvate, 50 U/ml
penicillin, and 50 µg/ml streptomycin (Invitrogen).

MeWo and SK-Mel-28 cell lines were

grown in Minimum Essential Medium (MEM) supplemented with 10% fetal calf serum, 50U/ml
penicillin, and 50µg/ml streptomycin. Peripheral blood lymphocytes (PBL) from healthy normal
donors were used as controls.

Paraffin-embedded archival tissue (PEAT) specimens were

obtained from melanoma patients who underwent surgical resection at Shinshu University
Hospital (Nagano, Japan) between 1999 and 2009. All of these specimens were initially assessed
by surgical pathologists at Shinshu University Hospital and diagnosed as melanoma.
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Quantitative Real-time (qRT)-PCR assay. Total RNA was extracted from cell lines and
PBL specimens using Tri-Reagent (Molecular Research Center Inc).
sequences

used

were:

5’-

The THAP5 primer

GAAAGGTGCACGCAAAGTTAAT-3’

CAGGAGTAAAATGGTCACTACATAGAA-3’ (reverse).

(forward);

5’-

The glyceraldehyde-3-phosphate

dehydrogenase (GAPDH) primer sequences were: 5’- CCATGTTCGTCATGGGTGT -3’
(forward); 5’- CCAGGGGTGCTAAGCAGTT -3’ (reverse). For cell lines and PBL specimens,
reverse transcription (RT) reactions were performed using Moloney murine leukemia virus RT
(Promega) with oligo-dT primer. The qRT-PCR assay was performed with the LightCycler
System and Universal Probe Library Set, Human (Roche Applied Science) using 250 ng of total
RNA.

Specific plasmid controls of THAP5 and GAPDH were synthesized as described

previously [73], and standard curves for each gene were generated with a threshold cycle of six
serial dilutions of plasmid templates (106–101 copies). THAP5 expression was calculated as a
ratio of THAP5 /GAPDH copy numbers.
Immunohistochemistry. Immunohistochemistry was performed on formalin-fixed, paraffin
embedded sections from primary and metastatic melanoma tissues. After deparaffinization,
endogenous peroxidase was quenched with peroxidase block (Fisher Scientific). For antigen
retrieval, the sections were boiled using microwave for 20 minutes in 10 mmol/L citrate buffer
(pH 6.0), and exposed to blocking solution (Protein Block Serum-Free, DakoCytomation). The
sections were incubated with polyclonal anti-THAP5 antibody for 60 minutes.

For

immunohistochemical detection, HRP-labeled anti-rabbit immunoglobulin antibodies (DAKO
EnVision+ System, HRP, DakoCytomation) was used (AEC + Substrate-Chromogen,
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DakoCytomation). Sections were counterstained via Gill’s hematoxylin (Fisher Scientific), and
then mounted [74].
Sub-cellular localization of THAP5 protein. To investigate the subcellular localization
of the THAP5 protein, the full-length cDNA (aa 1-395) was cloned in frame into EGFPC1 vector (Clontech).

MeWo cells were grown on glass cover slips in 12-well plates.

Approximately 60% confluent cells were transiently transfected with 1 µg of the GFP-THAP5
plasmid using Lipofectamine 2000 Transfection Reagent (Invitrogen). Twenty-four hours after
transfection, cells were washed and fixed in 4% paraformaldehyde, permeabilized with 0.2%
Triton X-100.

The cover slips were then washed and placed on microscope slides using

mounting solution with DAPI to stain the nucleus. Slides were observed using a LSM510
Confocal laser-scanning microscope (Zeiss).
Western blot analysis of THAP5 protein expression. Cell lysates were prepared using
RIPA buffer (150 mM NaCl, 50 mM TrisHCl, pH 7.5, 1% Nonidet P-40, 0.25% deoxycholic
acid sodium salt) containing the protease-inhibitor cocktail (Roche) and resolved by SDS-PAGE.
They were then electro-transferred onto a polyvinylidene difluoride (PVDF) membrane and
probed with polyclonal THAP5 antibody at a 1: 5000 dilution followed by secondary goat antirabbit horseradish peroxidase conjugated antibody [72]. The immunocomplex was visualized
using enhanced chemiluminescence (Pierce).
Cell death assays. MeWo cells were grown in six-well plates in the appropriate medium
until they reached 90% confluency followed by treatment for 10h with increasing concentrations
of cisplatin (1mM, 5mM, 10mM and 15mM respectively). For UV-irradiation, cells were treated
for 10h with increasing doses of UVC (25 mj/cm2, 30 mj/cm2, 35 mj/cm2, 40 mj/cm2 and 50
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mj/cm2 respectively) using a Spectroline UV crosslinker (254nm) [75, 76]. Cells were detached
with 1x Trypsin-EDTA (Gibco) and washed twice with ice-cold PBS. One-half of them were
used for Western blot analysis, and the rest for apoptotic assay.

Western Blot analysis

was performed as described. The apoptotic assay was performed according to BD Biosciences
protocol.

Briefly, cells were suspended in 1x binding buffer and stained with Annexin V

(apoptotic cell) and 7-amino-actinomycin D (7-AAD for necrotic cells). Samples were analyzed
on a FACS Calibur Flow Cytometer (BD Biosciences) [37]. For the other apoptotic assay,
MeWo cells were transfected with GFPC1 (control) and GFPC-THAP5 plasmids. Thirty six
hours after transfection, cells were treated with 50mj/cm2 of UVC. 10 hours following UVC
treatment the cells were stained with Annexin V and 7-AAD. Approximately ten thousand GFP
positive cells were counted the percentage of apoptotic cells estimated [72].
Electrophoretic Mobility Shift Assay (EMSA).

THAP5 DNA-binding assays were

performed as described previously [77, 78]. Briefly, nuclear extracts were prepared from
cultured MeWo and NIH3T3 cells in hypertonic buffer (20 mM HEPES, pH 7.9, 420 mM NaCl,
1 mM EDTA, 1 mM EGTA, 20% glycerol, 20 mM NaF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM
DTT, 0.5 mM PMSF, 0.1 mM aprotinin, 1 mM leupeptin, 1 mM antipain). Extracts containing
3 g of total protein were incubated with a double-stranded 32P-radiolabeled WT oligonucleotide
probe (5’-TGCCTGGTGCAAGTAACT) and mutant probe (5’-TGCCTGGTACACGTAACT).
Protein-DNA complexes were resolved by non-denaturing polyacrylamide gel electrophoresis
(PAGE) and detected by autoradiography.
Cyclic Amplification and Selection of Targets (CASTing). The CASTing procedure
described by Wright et al was modified to select for the THAP5 binding site [79, 80]. A
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randomized DNA template, 5’-TGG GCA CTA TTT ATA TCA A-N25- AAT GTC GTT GGT
GGC CC-3’ (where N25 is a 25-base sequence of randomly inserted nucleotides) was
synthesized

and

amplified

with

ACCGCAAGCTTGGGCACTATTTATATCAAC-3’

the
and

primers

5’-

5’-GGTCTAGAGGGC

CACCAACGACAT T-3’ in a PCR reaction. PCR cycling conditions used were: 94oC for 2
minutes, 30 cycles of 94oC (20 sec), 50oC (20 sec) and 72oC (20 sec), with a final extension at
72oC (10 min). Approximately 6l of MeWo cell extract was incubated with the PCR product
for 30 minutes in 100 l of binding buffer (20 mM Tris, pH 7.5; 100 mM NaCl; 0.05% NP40;
0.5 mM EDTA; 100 μg/ml BSA; 50 μg/ml Poly dI-dC; 5μg/μl single stranded salmon sperm
DNA) at RT. This was followed by addition of THAP5 specific antibody and Protein G-agarose
beads. After 30 minute incubation, the mixture was washed five times in 100 l of NT2 buffer
(20 mM Tris, pH 7.5; 100 mM NaCl; 0.05% NP40) [71]. Beads were resuspended in 100 μl of
H2O, and THAP5 bound DNA was purified by phenol/chloroform extraction and ethanol
precipitation and then resuspended in 10 μl of H2O. Two microliters of DNA isolated from the
first round of THAP5 binding were used in a second round of PCR amplification and purification
using the same conditions. After seven rounds of PCR amplification (with reduced number of
PCR cycles for the next round of CASTing), the oligonucleotides enriched for THAP5 DNA
binding site were into the pGEM-T Easy vector (Promega). Twenty five randomly selected
clones were sequenced and analyzed using the Multiple EM for Motif Elicitation (MEME)
software (meme.sdsc.edu).
Bioinformatics Analysis.

The software tool MEME was applied to the 25 sequences

generated from CASTing. The first motif that was found was much more significant than other
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reported motifs, with p-value at least 400 times smaller. By using the consensus of this motif,
GTGNAANNAAC, the upstream 1kb region plus 5' UTR of cell cycle genes that are reportedly
involved in G2/M transition were scanned according to methods described in [81]. The repeats in
these sequences were removed by Repeat Masker tool (http://www.repeatmasker.org/). A total
of 20 G2/M cell cycle genes were used as input and by allowing one nucleotide mismatch, 15
genes were found to contain at least one instance of to the consensus.
Reporter Gene Studies. 293T cells were seeded into 48-well plates to be 50-70% confluent
the next day.

Cells were transfected with Gal4 TK-Luc reporter and pRL-SV40 Renilla

luciferase (Promega), Gal4 DNA-binding protein (DBD) alone, Gal4 DBD-THAP5, or Gal4
DBD-THAP7 in increasing concentrations (0ng, 5ng, 25ng) using Lipofectamine 2000
(Invitrogen). PCDNA3 was used to maintain the total concentration of transfected DNA [70].
Cells were lysed after 48 h and luciferase activity was measured according to the manufacturer's
instructions (Promega).
Mutation Analysis. Three exon regions corresponding to THAP5 were amplified by PCR
from cDNA obtained from several melanoma cell lines, primary melanocytes and metastatic
melanoma samples. The following specific primers were used for Exon1 (677 bp): Forward 5’GAGTCGACAGACGAGGCGG -3’, Reverse 5’- CATTCCGGGCCTCAGTTTCC -3’; Exon2
(386

bp):

Forward

5’-

CTCTCCCACCTGATCACCTG
GCTTGGCCAGTGTACTACTC

CCTCTTGTAGTACTTACTTGAG
-3’;

and

-3’, Reverse

Exon3

(1200

-3’,
bp):

Reverse

5’-

Forward

5’-

5’- CTCTCCAGCCCAACTCTCTG

-3’.

Following amplification, the PCR products were sequenced and analyzed by ClustalW alignment
software.
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Statistical analysis. All quantitative data are expressed as mean ±SD. Differences among
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s Post-hoc
test. A value of P<0.05 was considered significant.
Results
Expression of THAP5 in melanoma cells/tissues . THAP5 is highly expressed in the
human heart, however the lack of availability of human cardiomyocyte cell lines restricts the
experiments we can perform to characterize the protein. This prompted us to use a different
system to study the function of THAP5. We originally isolated THAP5 from a melanocyte
cDNA library. Before we proceeded with the use of melanoma cells as a model system, we
performed RT-PCR analysis on several cell lines including melanoma and some other cancer
cells along with normal kidney cells taken as control. We found that THAP5 is highly expressed
in some of the melanoma cell lines and not expressed in normal kidney cells (Figure 10A). We
obtained human primary and metastatic melanoma tissues and used THAP5 antibody to probe
these tissues for THAP5 expression. We found that THAP5 shows high levels of staining in
both primary and metastatic melanoma (Figure 10B).
Sub-cellular localization of the THAP5 protein.

We have previously shown that

THAP5 is localized in the nucleus in Hela cells [72]. To verify that THAP5 has a similar
subcellular location in melanoma, we cloned the cDNA sequence corresponding to the fulllength THAP5 protein into the GFPC1 vector. The GFP-THAP5 vector was transfected into
MeWo cells and 24 hours later the subcellular localization of the protein was observed using a
Confocal microscope as previously described [72]. Figure 11 shows that, the full-length GFPTHAP5 protein is exclusively localized in the cell nucleus but is excluded from the nucleoli.
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THAP5 protein is induced in melanoma cells upon UV treatment . In order to
investigate whether THAP5 protein is regulated during apoptosis, MeWo cells were treated with
increasing doses of UVC and subsequently cell death was measured by Annexin V staining and
Flow Cytometry [72]. THAP5 protein level was monitored by Western blot analysis of cell
extracts, following UVC treatment and was found to be significantly induced in cells in a dose
dependent manner (Fig. 12 A, B). THAP5 induction corresponded with increased apoptosis,
both under conditions of increasing doses of UV and increasing time points. (Fig. 12 C, D).
Similar result was obtained using another melanoma cell line Sk-Mel28.
THAP5 protein level dramatically increases in MeWo cells following cisplatin
treatment. Cisplatin is another chemical that is known to activate DNA damage pathways. In
order to investigate whether cisplatin causes a change in levels of THAP5, MeWo cells were
treated with increasing doses of cisplatin and cell death was measured by Annexin V staining
and Flow Cytometry [72]. THAP5 protein levels were monitored by Western blot analysis of
cell extracts and found to be significantly increased in cells in treated with increasing doses of
cisplatin. This induction also correlated with a corresponding increase in percentage of apoptotic
cells (Figure 13). Similar results were obtained using another melanoma cell line SK-Mel28.
THAP5 sensitizes cells to UV induced cell death .

To test whether THAP5 is

proapoptotic or cytoprotective, MeWo cells were transfected with GFPC1 (control) and GFPCTHAP5 plasmids. Thirty six hours after transfection, cells were treated with increasing doses of
UVC. 10 hours following UVC treatment the cells were stained with Annexin V and 7-AAD.
Among the GFP-positive cells, the percentage of apoptotic cells was estimated. We found that in
cells overexpressing GFP-THAP5, there was increased cell death compared to those expressing
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GFP alone (Figure 14). This clearly shows that THAP5 sensitizes MeWo cells to UVC induced
apoptosis [37, 72].
THAP5 can repress transcription of a reporter gene . THAP proteins are reportedly
nuclear transcription factors with the ability to directly regulate expression of target genes. In
fact, transcriptional regulation activity has been shown before in THAP1, THAP7 and THAP11
[43, 58, 60, 70]. Therefore, we expected THAP5 to be such a transcription regulator based on
amino acid sequence similarity with the rest of proteins of the THAP-family. Since we do not
know the target genes that might be regulated by THAP5, we used a transcription repression
system that targets the Gal4-THAP5 to a reporter gene containing four Gal4 DNA binding sites.
Gal4-THAP5 was able to repress the transcription of Gal4 reporter gene (Figure 15). As a
positive control for these experiments we used Gal4-THAP7 previously shown to be a potent
repressor of transcription when used in the same system [70]. Gal4-THAP5 repressor activity
was not as effective as the THAP7 suggesting these two proteins might have distinctly different
functions.
Mutation Analysis of THAP5 gene. THAP5 is known to arrest cells at G2/M phase of the
cell cycle [72]. However, it is also highly expressed in several cancer cell lines and tissues in
very high levels. We wanted to test if the THAP5 gene is mutated. So using specific primers,
we amplified the three different exons of THAP5 from cDNA obtained from several obtained
from several melanoma cell lines, primary melanocytes and metastatic melanoma tissues and
sequenced them. However,

we found no mutations in THAP5. This suggests that THAP5 is

highly expressed in melanoma cell lines but not degraded and this could account for some unique

45

function in cancer cells. Figure 16 shows a schematic diagram representing the three exons of
THAP5 gene.
Characterization of THAP5 binding site. THAP5 has an atypical zinc finger domain
(THAP domain) at its amino terminus which has been shown to be a sequence-specific DNAbinding domain in THAP1 and mouse homolog of THAP11 (Ronin) [44, 71]. Based on this
information, we expected THAP5 to bind to a specific DNA sequence. To determine whether
the THAP domain of THAP5 possesses sequence-specific DNA-binding activity and identify a
consensus target-binding site, we used a modified PCR-based approach, CASTing (Cyclic
Amplification and Selection of Targets) [79, 80]. We synthesized an approximately 100 bp
random oligonucleotide using specific primers.

This oligonucleotide pool was mixed with

MeWo cell extract to permit the formation of THAP5/DNA complexes and then
immunoprecipitated with Protein-G agarose beads and anti-THAP5 polyclonal antibody. The
protein-DNA complexes were washed and then re-amplified. This process was repeated six
times to enrich for oligonucleotides bound to THAP5 and after the seventh round, the PCR
product was cloned into suitable vector (described in methods) and sequenced. Figure 17 A
shows a consensus DNA binding site specific to THAP5.
DNA-binding site specificity of THAP5.

To confirm the binding of THAP5 to the

consensus DNA binding site, we performed electrophoretic mobility shift assays (EMSA) [77,
78]. We used labeled oligonucleotides containing the THAP5 consensus sequence (WT 5’TGCCTGGTGCAAGTAACT), resolved the protein-DNA complexes by non-denaturing
polyacrylamide gel electrophoresis (PAGE) and detected the bands by autoradiography. Figure
17B shows specific binding of THAP5 to the consensus sequence in MeWo extracts. Use of a
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THAP5 specific antibody significantly reduced the binding of the complex. In addition, we do
not see any binding of THAP5 in NIH3T3 mouse extracts (which lack THAP5 protein), showing
that the DNA binding site is highly specific to THAP5. We also used 100 molar excess of cold
probe (WT and mutant) and found that the binding of THAP5 was abolished completely. We
mutated the consensus DNA binding site by modifying the invariable G and A nucleotides at
positions 3 and 6, and found that the binding of THAP5 to the mutant probe was significantly
diminished (Fig 17C).
Identification of THAP5 binding site in promoter of G2/M genes.

In previous

studies, THAP1, THAP11 and the mouse homolog of THAP11 (Ronin) were shown to bind a
specific DNA sequence and regulate transcription of specific genes RRM1, c-Myc and HCF-1
respectively [44, 60, 71]. We know THAP5 is present exclusively in the cell nucleus and ectopic
expression of THAP5 induces G2/M arrest in transfected cells [72]. Therefore, if THAP5 is
indeed a transcription factor, one of its functions will be direct regulation of genes involved in
cell-cycle.

Based on this information and using the consensus THAP5 binding motif,

GTGNAANNAAC, nucleotides spanning the 1kb region upstream of the promoters including 5'
UTR of known cell cycle genes involved in G2/M transition [81] were scanned using specific
software described in the methods section. A total of 20 G2/M genes were used as input and by
allowing one nucleotide mismatch, 15 promoters were found to contain at least one instance of
the consensus (shown in figure 16) (described in methods).
Discussion
THAP proteins are characterized by the presence of a THAP domain at the N-terminus with
specific conserved residues and these include, a C2CH zinc finger motif, three other residues
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(P26, W36, F58) and a C-terminal AVPTIF box (Ala-Val-Pro-Thr-Ile-Phe), which have been
shown to be essential for the DNA binding activity of these proteins [38]. Abolishing any of
these key residues eliminates DNA binding activity [44, 82]. In this study, we have expanded our
studies on THAP5, one of the twelve human THAP proteins.

For this purpose, we used

melanoma cells because we originally isolated THAP5 as an interactor of Omi/HtrA2 using a
melanocyte library and it is also expressed in melanocytes /melanoma.
We performed RT-PCR analysis of several cancer cell lines and found THAP5 to be highly
expressed in several melanoma cell lines but not in normal cells.

Moreover primary and

metastatic melanoma tissues also show high levels of expression of THAP5. This raises a
question as to why a protein which is involved in cell cycle arrest would be highly expressed in
cancer cells. This could be the result of some mutation in THAP5 gene in these cells. To test
this, we performed mutation analysis of several of the melanoma cell lines and metastatic
melanomas using PCR amplification of the three exons encoding for THAP5 gene followed by
sequencing of the exons. However, we found no mutations in the THAP5 gene. This suggests
that THAP5 plays is highly expressed but not targeted for degradation. The stabilization of
THAP5 could account for it function in melanoma cells and other cancers. We have previously
shown that THAP5 contains a nuclear localization signal able to translocate the protein to the
nucleus of HeLa cells [72]. To verify that THAP5 is also nuclear in melanoma cells we
transfected MeWo cells with GFP-THAP5 fusion protein. These experiments clearly showed
GFP-THAP is exclusively nuclear.
Some of the THAP proteins have been implied in functions such as apoptosis and cell cycle
control.

THAP0/DAP4 was originally identified while screening a Hela library for IFN-
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induced apoptosis genes [57]. It is speculated that THAP0/DAP4 may promote MST1-induced
apoptosis by enabling the colocalization of MST-1 protein with p53 [69]. Also, THAP1 has
been shown to be a proapoptotic protein associated with promyelocytic leukemia nuclear bodies
(PML NBs), which interacts with Par-4 and induces serum withdrawal and TNF-induced
apoptosis [45]. Par-4 is a transcriptional regulator which is upregulated in prostate cancer cells
undergoing apoptosis [83, 84].

Additionally, overexpression of Par-4 in neurons, prostate

cancer and melanoma cells also sensitizes these cell types to apoptosis [43]. To investigate
THAP5’s role during apoptosis in melanoma, we treated MeWo cells with UVC. We used UVC
to induce apoptosis because it is the most relevant physiological stimulus for these cells and it is
also known to be responsible for the development melanoma cancers. In MeWo cells, upon
treatment with UVC, we found that THAP5 is considerably induced and this increase correlated
with the degree of apoptosis in the cell population. Similar results were obtained using a
melanoma cell line, SK-Mel28.
The induction of THAP5 in melanoma cells treated with UV could have a pro-apoptotic or
cytoprotective function.

To test this we transfected MeWo cells with GFP-THAP5.

We

irradiated these cells with increasing doses of UVC and found that GFP-THAP5 over-expressing
cells were more sensitive to UVC radiation compared to cells expressing GFPC vector alone.
This suggests that THAP5 has a proapoptotic function in melanoma cells treated with UV.
We investigated whether UV alone can induce THAP5 or other cytotoxic chemicals known to
cause DNA damage can have a similar effect. For these experiments, MeWo cells were treated
with cisplatin.

Cisplatin forms adduct with DNA and the resulting inter and intra strand

crosslinks disrupt the structure of the DNA thereby interfering with replication and transcription
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processes [85]. This alteration in the structure is recognized by the cellular proteins to repair
cisplatin-induced DNA damage [85]. THAP5 protein was also induced when melanoma cells
were treated with cisplatin in a similar manner as cells treated with UV. These results suggest
THAP5 is probably involved in a previously unknown pathway that gets activated by DNA
damage leading to cell death.
THAP proteins constitute the second largest family of zinc finger proteins after the C2CH family
[82]. The few members that have been studied were shown to have DNA binding activity and to
recognize specific target sequences. THAP1 binds to an 11 nucleotide motif and Ronin (mouse
homolog of THAP11) recognizes a slightly longer and different 15 nucleotide sequence [44, 71].
These findings as well as recent structural analysis has speculated that each THAP protein may
bind to a unique DNA sequence and therefore perform a distinct function in cells where it is
expressed [44, 71, 86]. We employed a modified protocol of the Cyclic Amplification and
Selection of Targets (CASTing) assay and identified an 11 nucleotide consensus binding
sequence recognized by THAP5 [79, 80]. To verify that THAP5 can bind to this sequence in
cells we performed electrophoretic mobility shift assays (EMSA). We confirmed the specificity
of binding by using THAP5 specific antibody which reduced the binding significantly. Not only
does the probe bind to THAP5 specifically but also shows no binding in mouse nuclear extracts
(NIH3T3) which lack THAP5. We mutated the two nucleotides which were invariable in all
sequences (G3 and A6) and found that the binding of THAP5 to the sequence is considerably
reduced.
It has been proposed that some members of the THAP family of proteins (THAP7 and HIM-17)
play a role in chromatin regulation because of their interaction with chromatin-modifying
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proteins [58, 70]. THAP7 has been shown to associate with histone tails, HDACs and NCoRs
[58, 70] and act as a transcriptional repressor. HIM-17 is involved in recruitment of the
methyltransferase activity to histone H3 [87, 88]. Ronin interacts with HCF-1, an important
transcriptional regulator [71].
Since there’s no information on the potential gene targets of THAP5, we first performed a
transfected reporter gene assay. For this assay, we used THAP5 fused to a Gal4 DNA binding
domain and cotransfected it with a vector containing the firefly luciferase gene under the control
of Gal4 binding sides and a control Renilla luciferase reporter. We measured the luciferase
activity relative to the Renilla luciferase values. As a control for this experiment we used Gal4THAP7 which has already been shown to be a transcription repressor [58, 70]. Gal4-THAP5
shows repressor activity but it was not as high as the Gal4-THAP7. Although at this point, we
have only demonstrated that THAP5 can function as a repressor in a heterologous system, we
still do not know if it can repress genes in cells and under what conditions this function comes
into play.
Some of the THAP proteins have been shown to exert their function by acting on specific gene
targets. THAP1 has been shown to act on RRM1 gene, a pRb/E2F cell cycle target [43].
THAP11 represses c-Myc and negatively downregulates growth of cells [60]. Since we already
know the specific DNA sequence that THAP5 binds to, we decided to look for this binding site
in promoters of genes which are involved in G2/M transition. The reason we did this was
because we have previously shown that THAP5 is involved in G2/M cell cycle arrest [72]. We
took a set of 20 known genes involved in G2/M cell cycle arrest. Using the consensus binding
site for THAP5 we scanned the promoter region of these genes and found the binding site in
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several of the genes. Of these genes, we are particularly interested in the sites that showed up
only in human, rhesus and dog because THAP5 is not expressed in mouse/rats.
Currently we are looking at a set of genes and using their promoter regions containing potential
THAP5 binding sites in luciferase assays to test if THAP5 regulates their transcription. It’ll be
interesting to identify potential targets of THAP5 because it can provide a lot of information on
THAP5’s functions in cells. As a starting point, it might be worthwhile to look into HCF-1, a
large protein involved in transcriptional control.

Previously, Ronin (mouse homolog of

THAP11) has been shown to associate with a large HCF-1 protein containing complex, in which
even THAP7 was pulled down [71]. Recently another group also showed that THAP1 and
THAP3 can interact with HCF-1 and activate transcription [89]. They also showed that most of
the THAP proteins have a HCF-1 binding motif called HBM through which they interact with
the amino-terminal kelch domain of HCF-1. The HBMs are always located upstream of the
coiled-coil domains and found at similar locations in the orthologs of THAP proteins in other
species such as zebrafish and xenopus [89]. In fact, in a yeast two hybrid screen, they showed
that most of the THAP proteins including THAP5 can interact with HCF-1 protein. Therefore, it
has been proposed that interaction of THAP proteins with HCF-1 may be important for both
transcriptional activation and repression, depending on the THAP protein involved, the cellular
context and/or the cell cycle status [89].
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Figure 10. Expression of THAP5 in melanoma cells and tissues.
A, qRT-PCR analysis of various cell lines showing THAP5 expression. qRT-PCR was performed on
several cell lines including melanoma and some other cancer cell lines with normal kidney cells as
control. THAP5 is highly expressed in some melanoma cell lines. B, Immunohistochemistry staining of
primary and metastatic melanoma tissues showing high levels of THAP5.
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Figure 11. Subcellular localization of the THAP5 protein in melanoma (Mewo) cells.
Confocal images of Mewo cells transfected with GFP-THAP51-395 shows exclusive nuclear
localization (green in A). Nomarski/DIC images of the same cells are shown in A'. Panel B
shows cells with DAPI staining for the nucleus and B’ shows merged image of Panels A, B and
A’.
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Figure 12. THAP5 protein is induced in MeWo cells upon UV treatment.
A, Cell death was monitored in the treated cell populations, by Annexin V and 7-AAD staining and
analyzed by flow cytometry; B, Cell extracts of the treated samples were prepared, followed by Western
blot analysis of the same. Lane 1 shows lysate from control cells; lanes 2, 3, 4, 5 and 6 show extracts
from MeWo cells treated with increasing doses of UVC; 25mj/cm2, 30mj/cm2, 35 mj/cm2, 40mj/cm2, 50
mj/cm2 respectively. THAP5 protein level increases with time. C, Cell death was monitored in the UVC
treated cell populations, by Annexin V and 7-AAD staining and analyzed by flow cytometry. D, cell
extracts were prepared followed by Western blot analysis of the treated samples. Lane 1 shows lysates
from control cells; lanes 2, 3, 4, 5 and 6 show extracts from cells treated with 50 mj/cm2 of UVC after 4,
6, 8 and 10 hrs respectively. β-Actin antibody was used to verify that equal amounts of protein were
present in each lane. Data are means ± SD of four independent experiments.
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Figure 13. THAP5 protein levels increase following cisplatin treatment.
MeWo cells were treated with increasing doses of cisplatin to induce apoptosis. A, Cell death was
monitored in the treated cell populations, by Annexin V and 7-AAD staining and analyzed by flow
cytometry. B, Cell extracts were prepared followed by Western blot analysis of the treated samples.
Lane 1 shows lysates from control cells; lanes 2, 3, 4, and 5 show cells treated with 1mM, 5mM, 10mM
and 15mM cisplatin for 10 hours respectively. β-actin antibody was used to verify that equal amounts of
protein were present in each lane. Data are means ± SD of four independent experiments.
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Figure 14. Overexpression of THAP5 sensitizes cells to UV induced apoptosis.
MeWo cells were transfected with GFPC vector and GFPC-THAP5 plasmids. 36 hours following
transfection, cells were treated with increasing doses of UVC. Cell death was monitored in the treated
cell populations, by Annexin V and 7-AAD staining and GFP positive cells were counted analyzed by
flow cytometry. Data are mean ± SD of 3 different experiments.
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Figure 15. THAP5 represses transcription of a reporter gene.
Gal4DBD-Thap5 and Gal4DBD-Thap7 were transfected separately in increasing amounts (0ng, 5ng and
25ng respectively) into HEK-293T cells along with Gal4 MH100TK-luc reporter and a control Renilla
luciferase reporter (pRL-SV40 Luc). Luciferase assays were performed 48 hrs post transfection. Values
are reported relative to Renilla Luciferase reporter. Data are means ± SD of four independent
experiments.
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Figure 16. Schematic representation of the THAP5 gene.
Full-length THAP5 gene contains 3 exons regions. Exon1 is 677 base pairs (bp), Exon2 is 386
bp and Exon 3 is 1200 bp long. The three exon regions depicted in the figure were amplified by
PCR from cDNA obtained from several melanoma cell lines, primary melanocytes and
metastatic melanoma tissues. Specific primers were used for amplification of the three exons
followed by sequencing and analysis of the PCR products for mutations.
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Figure 17. Identification of a THAP5 consensus DNA-binding site.
A, The 11-nucleotide THAP5 DNA binding site. The oligonucleotide sequences recovered after 7 rounds
of selection were analyzed by the motif-discovery program MEME. B, Electrophoretic Mobility Shift
Assay showing THAP5 binding to consensus sequence. Lane 1, control (no extract); lane 2, MeWo
nuclear extract; lane 3, MeWo extract with anti-THAP5 antibody; lane 4, NIH 3T3 extract; lane 5, MeWo
extract plus 100 molar excess of cold THAP5 specific probe (WT 5’-TGCCTGGTGCAAGTAACT ) and
lane 6, MeWo extract plus 100 molar excess of mutant probe (Mut 5’-TGCCTGGTACACGTAACT),
incubated with 32P labeled wild type probe. The protein-DNA complexes were analyzed by
electrophoretic mobility shift assay (EMSA) as described in methods. C, Specificity of THAP5 Binding.
First four lanes show THAP5 binding to the labeled WT probe. Lane 1, control (no extract); lane 2,
MeWo nuclear extract; lane 3, MeWo extract with anti-THAP5 antibody; lane 4, NIH 3T3 extract. Lanes
5-6 show reduced binding of THAP5 to the labeled Mutant probe. Lane 5, control (no extract); lane 6,
MeWo nuclear extract; lane 7, MeWo extract with anti-THAP5 antibody; lane 8, NIH 3T3 extract.
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Figure 18. Identification of potential promoters containing THAP5 binding site.
Using the consensus THAP5 binding motif, GTGNAANNAAC, nucleotides spanning the 1kb region
upstream of the promoters including 5' UTR of known cell cycle genes involved in G2/M transition were
scanned using the software listed in Materials and Methods. A total of 20 G2/M genes were scanned and
by allowing one nucleotide mismatch, 15 genes were found to contain at least one instance of the
consensus (shown in table).
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CHAPTER 4: GENERAL DISCUSSION AND CONCLUSIONS
Omi/HtrA2 is an extensively studied serine protease. Its role as a proapoptotic protease is very
well established however, its normal function in cells is not known [3, 5, 6, 11]. Most of the
recent studies seem to point out to a protective function for Omi/HtrA2 [19]. Some groups
believe it may be involved in the maintenance of cellular equilibrium. In order to define the
functions of a protein it is important to find out what other proteins it interacts with. The
interacting/partner protein sheds light on the possible pathways/ functions of the protein of
interest.

The yeast two-hybrid system is a popular method used to isolate new protein

interactors. We employed this method to discover new partners of Omi/HtrA2. Among the
approximately 30 interactors obtained, the one of most interest to us was THAP5. There was no
published information on this protein. The only known information on THAP5 was it belongs to
a large family of transcription factors called THAP proteins [45]. All the proteins in this family
have zinc dependent DNA binding activity and are involved in various important cellular
functions [45].
Through my dissertation we were able to obtain key information on the function of this novel
THAP5 protein. THAP5 is a 395 amino acid protein which localizes in the nucleus. It encodes
for an approximately 50kDa protein. THAP5 mRNA is highly expressed in the human heart and
some expression is seen in the brain and skeletal muscle. It interacts with Omi/HtrA2 in yeast
and in mammalian cells. However, in mammalian cells, THAP5 interacts with Omi/HtrA2 only
under conditions of apoptosis. When cells are subjected to apoptotic stimuli, Omi/HtrA2 is
released from the mitochondria and this creates a physiological meeting point for these two
proteins.

Furthermore, the interaction of Omi/HtrA2 with proteins from different cellular
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compartments has been well documented before. We have been able to show that THAP5 can
serve as a substrate for Omi/HtrA2 both in vitro and in mammalian cells. The degradation of
THAP5 can be prevented by the use of ucf-101, a specific inhibitor of Omi/HtrA2. However, it
is not known what the function of this degradation of THAP5 means [72].
To explore the normal function of THAP5, we overexpressed the protein in cells and found that
it induced cell cycle arrest at G2/M phase. This could possibly explain the high levels of
expression of THAP5 in the human heart which represents a terminally differentiated organ with
very small percentage of dividing cells. This function of THAP5 is also in agreement with some
other proteins of the THAP family. The most significant finding is the deregulation of THAP5
in heart tissues from Coronary Artery Disease (CAD) patients. This occurs in the myocardial
infarction area (MI), where maximum damage and loss of cardiomyocytes happens. Although
the actual function of THAP5 in the human heart is unknown at this point, its deregulation
coupled with the high expression levels in the human heart suggests that the protein plays a very
important role in the development/ progression in heart disease [72]. The absence of mouse/rat
homolog for THAP5 made studies with the proteins very difficult. Besides, there are no human
cardiomyocyte cell lines available. Therefore, we decided to use melanoma cells to study the
mechanism of THAP5 function, where we know THAP5 is expressed.
We found that THAP5 has a proapoptotic function in melanoma cells. THAP5 is not only
induced upon UV and cisplatin mediated apoptosis, its overexpression also sensitizes melanoma
cells to these apoptotic stimuli. Through our results, we believe that THAP5 could be involved
in a very important DNA damage/repair pathway. This function of THAP5, we believe is
independent of the Omi/HtrA2 pathway. We have also identified a DNA binding site which is
64

specifically recognized by THAP5. Although at this moment, we do not know the genes that
THAP5 regulates, we have narrowed down a list of G2/M phase genes that potentially contain
THAP5 binding site in the promoter region. Identifying the gene targets of THAP5 will provide
great insight into its function as a transcription factor. Furthermore, THAP5 can repress the
transcription of a reporter gene adding to the set of transcriptional repressors belonging to the
THAP family of proteins. In summary, our work identifies a novel cardiospecific transcription
factor with an important role in heart disease and melanoma apoptosis.
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